GYRE
GYRE THERAPEUTICS, INC.
Key Financials
Net Income
$9.9M
↓ 44.8%
Operating Income
$11.5M
↓ 28.9%
Revenue
$116.6M
↑ 10.2%
Gross Profit
$101.9M
↓ 6.4%
EPS (Diluted)
$0.02
↓ 60.0%
Total Liabilities
$23.9M
↓ 11.7%
Shareholders' Equity
$106.0M
↑ 67.5%
Total Assets
$166.1M
↑ 32.5%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 8-K/A | 4/17/2026 | View on SEC |
| PRE 14A | 4/16/2026 | View on SEC |
| 8-K | 3/23/2026 | View on SEC |
| 10-K | 3/13/2026 | View on SEC |
| 8-K | 3/12/2026 | View on SEC |
| 8-K | 3/12/2026 | View on SEC |
| 8-K | 3/2/2026 | View on SEC |
| 4 | 1/9/2026 | View on SEC |
| 4 | 1/9/2026 | View on SEC |
| 8-K | 1/5/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | GYRE |
| Company Name | GYRE THERAPEUTICS, INC. |
| CIK | 1124105 |
| Sector | Pharmaceutical Preparations |
| Industry | Accelerated filer Smaller reporting company |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | (858) 567-7770 |